Egis Gyogyszergyar

Egis Gyogyszergyar Rt.

Richter Gedeon Nyrt.

Richter Gedeon Vegyeszeti Gyar Rt

Other

Basf Aktiengesellschaft

Gis Gyogyszergyar Rt.

Egis Gyoyszergyar Rt

Egis Gyogyszergyat

Istvan Gyertyan

Istvan Gacsalyi

Lujza E Petocz

Marton Fekete

Gabor Gigler

Jozsef Reiter

Eva Schmidt

Gabor Blasko

Katalin Saghy

Gyula Simig

Bela Kiss

Eva Againe Csongor

Andras Egyed

Zoltan Budai

Eniko Szirt Nee Kiszelly

Frigyes Gorgenyi

Jozsef Barkoczy

Sandor Farkas

Judit Laszy

Katalin Szemeredi

Laszlo Pongo

Maria Szecsey Nee Hegedus

Andras Bilkei-Gorzo

Jozsef Knoll

Tibor Mezei

Imre Moravcsik

Attila Mandi

Ferenc Andrasi

Tamas Hamori

Janos Galambos

Pal Berzsenyi

Gyorgy Domany

Klara Reiter Nee Esses

Daniel Bozsing

Katalin Nogradi

Gabor Zolyomi

Gizella Bartane Szalai

Berta Knoll

Pal Vago

Eszter Szentkuti

Karoly Tihanyi

Anna Bakonyi

Endre Rivo

Judit Bajnogel

Katalin Horvath

Gyorgyne Mate

Zsolt Komlodi

Gabriella Zsilla

Edit Horvath

Gyorgy Hajos

Pal Benko

Istvan Laszlovszky

Gabor Nemeth

Jozsef Nagy

Imre Klebovich

Laszlo Pallos

Andras Messmer

Peter Tompe

Istvan Borza

Edit Berenyi Nee Poldermann

Csilla Horvath

Gyula Lukacs

Gyorgy Somogyi

Sandor Kolok

Katalin Pallagi

Istvan Vago

Monika Vastag

Katalin Budai Nee Simonyi

Imre Doman

Maria Hegedus

Klara Kazo Nee Daroczi

Enik Szirt Nee Kiszelly

Aniko Miklos Nee Kovacs

Amrita Agnes Bobok

Jeno Korosi, Deceased

Gyoergy Domany

Edit Berenyi Ne Poldermann

Norbert Antal Kirschner

Ne Simonyi Budai

Zsuzsa Juhasz Nee Riedl

Josef Reiter

Josef Barkoczy

Luiza Petocz

Klara Reiter Nee Eszes

Ludmilla Rohacas Nee Zamkovaja

Ottilia Elekes

Kalara Reiter Nee Esses

Peter Korosi

Ildiko Ratz Nee Simonek

Klara Daroczi Kazone

Gyula Balogh, Deceased

Erzsebet Kaufmanne Bojti

Cecilia Salamon Haskane

Ivan Jakoczi

Hilda Botka

Andras Bilkei Gorzo

Miklos Abermann

Katalin Baloghne Nemes

Gyula Grezal

Erszebet Birkas

The present invention relates to new dopamine Dand Dligands of formula (I): wherein R1, R2 and Q are as described herein, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates and/or polymorphs thereof. The invention also relates to processes for preparing the same, to compositions containing the same and to their use in the treatment and/or prevention of conditions which requires modulation of dopamine receptors.

[object Object]

The present invention relates to metabolites of(thio)-carbamoyl cyclohexane derivatives, particularly, metabolites of trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine and pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing the same and to their use in the treatment and/or prevention of a conditions which requires modulation of dopamine receptors.

Metabolites of (thio) carbamoyl-cyclohexane derivatives

Provided herein are Thieno[2,3-b]pyridine compounds with mGluR activity. Also provided herein are processes and intermediates for the preparation of the Thieno[2,3-b]pyridine compounds, pharmaceutical compositions containing these compounds, and the use of these compounds in treatment, therapy, and/or prevention of conditions which require modulation of mGluR1 and mGluR5 receptors.

Thieno [2,3-b] pyridine compounds with mGluR activity

The present invention relates to new 4-benzylidene-piperidin derivatives of formula (I), useful as NMDA, in a particular NR2B subunit containing receptor antagonists and analgesica. 

4-benzyledene-piperidin derivatives

The present invention relates to new D3 and D2 dopamine receptor subtype preferring ligands of formula (I): wherein Rand Rrepresent independently a substituent selected from hydrogen, alkyl, aryl, cycloalkyl, aroyl, or Rand Rmay form a heterocyclic ring with the adjacent nitrogen atom; X represents an oxygen or sulphur atom; n is an integer of from 1 to 2, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof, to the processes for producing the same, to pharmaceutical compositions containing the same and to their use in therapy and/or prevention of a condition which requires modulation of dopamine receptors.

(Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists

The present invention relates to new dopamine Dand Dand serotonin 5-HTreceptor subtype preferring ligands of formula (I); wherein A represents alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or a group of formula &#x2014;NRR, wherein Rand Rrepresent independently a substituent selected from hydrogen, alkyl, alkenyl, aryl, heteroaryl or cycloalkyl or Rand Rform with the adjacent nitrogen atom and optionally with further heteroatom(s) a heterocyclic ring; m is an integer of 0 to 1; n is an integer of 1 to 2, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof, to the processes for producing the same, to pharmacological compositions containing the same and to their use in therapy and/or prevention of a condition which requires modulation of dopamine and/or 5-HTreceptors. 

Piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions

1,7,7-trimethyl-bicyclo[2.2.1]heptane derivatives as anxiolytic agents

The invention relates to new 1-[2-(substituted vinyl)]-3,4-dihydro-5H-2,3-benzodiazepine derivatives, a process for the preparation thereof and pharmaceutical compositions comprising them. The new 1-[2-(substituted vinyl)]-3,4-dihidro-5H-2,3-benzodiazepine derivatives according to the invention correspond to the general formula (I), ##STR1## wherein the variables are hereinbelow defined: The new compounds according to the invention affect the central nervous system and can be used to advantage in the therapy.

1-[2-(substituted vinyl)]-3,4-dihydro-4-dihydro-5H-2,3-benzodiazepine

This invention relates to new 1-�2-(substituted vinyl)!-5H-2,3-benzodiazepine derivatives, a process for the preparation thereof, pharmaceutical compositions comprising the same, to the use of the said benzodiazepine derivatives for the treatment of diseases and for the preparation of pharmaceutical compositions suitable for the treatment of diseases. The compounds according to the invention correspond to the general formula (I), ##STR1## wherein the variables are herein below defined, and the compounds possess central nervous activities.

1-�2-(substituted vinyl)!-5H-2,3-benzodiazepine derivatives

The invention relates to anxiolytic pharmaceutical compositions comprising as active ingredient 1-sytrylisoquinoline derivatives of general formula (I), wherein

Heterocyclic compounds, pharmaceutical compositions comprising them and

Novel basic ether of general formula (I), ##STR1## wherein R.sup.1 and R.sup.2 are independently hydrogen, halogen or C.sub.1-4 alkoxy, or together they represent a 3,4-methylenedioxy group,

Basic ethers and process for the preparation thereof

The invention relates to novel, pharmaceutically active benz[e]indene derivatives, a process for the preparation thereof, pharmaceutical compositions comprising the same, further to the use of the said benz[e]indene derivatives in the treatment of certain diseases and in the preparation of pharmaceutical compositions suitable for the treatment of said diseases. The new benz[e]indene derivatives according to the invention correspond to the general formula ##STR1## wherein A represents a group of the formula alk-NR.sup.1 R.sup.2, wherein alk represents a C.sub.2-7 alkylene group optionally carrying a hydroxy substituent,

Benz[e]indene derivatives

The invention relates to novel triazolyl thioamides of the general formula (I), ##STR1## wherein Q represents hydrogen or a heterocyclic group optionally bearing one or more C.sub.1-4 alkyl substituent(s), or a group of the formula SR.sup.1, wherein

Triazolyl thioamide derivates

Growing community of inventors

Budapest, Hungary

Istvan Gyertyan